Drug Profile
Padsevonil - UCB
Alternative Names: UCB-0942; UCB1415943-000Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator UCB
- Class Antiepileptic drugs; Imidazoles; Pyrrolidinones; Small molecules; Thiadiazoles
- Mechanism of Action GABA A receptor agonists; Neurotransmitter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in Japan (PO, Tablet)
- 08 Feb 2022 UCB pharma terminates a phase II trial in Epilepsy (Adjunctive treatment, Treatment-resistant) (PO) in Netherlands, Germany, Belgium, Hungary, Italy, Spain, Bulgaria (EudraCT2015-001268-20) (NCT02625090)
- 03 Jan 2022 UCB Biopharma terminates phase II/III trial in drug-resistant Epilepsy in USA, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia,Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Lithuania, Mexico, Poland, Romania, Serbia, Slovakia, Spain, Turkey and United Kingdom